Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long-acting injectable antiretrovirals for HIV treatment and prevention

Long-acting injectable antiretrovirals for HIV treatment and prevention REVIEW URRENT Long-acting injectable antiretrovirals for HIV PINION treatment and prevention a a b William R. Spreen , David A. Margolis , and John C. Pottage, Jr. Purpose of review Long-acting antiretroviral (ARV) drugs may improve adherence to therapy and extend opportunities for therapeutic or prophylactic intervention to underserved patient populations. This review focuses on recent advances in the development of small molecule long-acting injectable ARV agents. Recent findings The need for combination ART and physicochemical and dosing limitations of current ARV drugs impede attempts to redevelop them as long-acting injectable formulations. However, the intrinsic properties of rilpivirine, a nonnucleoside reverse transcriptase inhibitor, and GSK1265744, an HIV-1 integrase strand transfer inhibitor, have enabled crystalline nanoparticle formulations to progress to clinical trials. Summary Investigational long-acting injectable nanoformulations of rilpivirine and GSK1265744 are clinical-stage development candidates. Complementary pharmacologic properties of both agents – different mechanisms of action, resistance profiles, metabolic pathways, lack of drug interactions and low daily oral doses – offer the potential for combination use. Phase I studies of the pharmacokinetics and safety of each long- acting formulation alone and in combination indicate that a monthly dosing regimen is possible for HIV treatment. An ongoing phase IIb trial of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Long-acting injectable antiretrovirals for HIV treatment and prevention

Current Opinion in HIV and Aids , Volume 8 (6) – Nov 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/long-acting-injectable-antiretrovirals-for-hiv-treatment-and-OPmQ2pAW6F

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000002
pmid
24100877
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT Long-acting injectable antiretrovirals for HIV PINION treatment and prevention a a b William R. Spreen , David A. Margolis , and John C. Pottage, Jr. Purpose of review Long-acting antiretroviral (ARV) drugs may improve adherence to therapy and extend opportunities for therapeutic or prophylactic intervention to underserved patient populations. This review focuses on recent advances in the development of small molecule long-acting injectable ARV agents. Recent findings The need for combination ART and physicochemical and dosing limitations of current ARV drugs impede attempts to redevelop them as long-acting injectable formulations. However, the intrinsic properties of rilpivirine, a nonnucleoside reverse transcriptase inhibitor, and GSK1265744, an HIV-1 integrase strand transfer inhibitor, have enabled crystalline nanoparticle formulations to progress to clinical trials. Summary Investigational long-acting injectable nanoformulations of rilpivirine and GSK1265744 are clinical-stage development candidates. Complementary pharmacologic properties of both agents – different mechanisms of action, resistance profiles, metabolic pathways, lack of drug interactions and low daily oral doses – offer the potential for combination use. Phase I studies of the pharmacokinetics and safety of each long- acting formulation alone and in combination indicate that a monthly dosing regimen is possible for HIV treatment. An ongoing phase IIb trial of

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: Nov 1, 2013

There are no references for this article.